Top

Published in:

01-04-2011

Variation of Heart-to-Mediastinal Ratio in ¹²³I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections

Authors: Wengen Chen, Qi Cao, Vasken Dilsizian

Published in: Current Cardiology Reports | Issue 2/2011

Abstract

Studies have repeatedly shown the utility of ¹²³I-mIBG cardiac sympathetic imaging for identifying symptomatic heart failure patients most likely to experience adverse cardiac events. Delayed heart-to-mediastinal ratio (H/M) and washout rate derived from meta-iodobenzylguanidine (mIBG) scintigraphy have been used to monitor response to medical treatment. However, there is great variation of H/M ratio among publications from various institutions. The current article systemically reviews factors that can potentially affect H/M ratio, particularly the acquisition parameters, and proposes new approaches and/or procedures to standardize the imaging procedure and minimize the variation of H/M among institutions.

Nakajo M, Shimabukuro K, Yoshimura H, et al.: Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986, 27:84-89.PubMed

Wieland DM, Brown LE, Rogers WL, et al.: Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981, 22:22-31.PubMed

Kline RC, Swanson DP, Wieland DM, et al.: Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981, 22:129-132.PubMed

Dilsizian V, Chandrashekhar Y, Narula J: Introduction of New Tests: Low are the mountains, high the expectations. JACC Cardiovasc Imaging 2010, 3:117-119.CrossRefPubMed

Flotats A, Carrio I: Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004, 11:587-602.CrossRefPubMed

Carrio I, Cowie MR, Yamazaki J et al.: Cardiac sympathetic imaging with mBIG in hear failure. JACC Cardiovasc Imaging 2010, 3:92-100.CrossRefPubMed

Gerson MC, Craft LL, McGuire N, et al.: Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002, 9:608-615.CrossRefPubMed

Verberne HJ, Brewster LM, Somsen GA, et al.: Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008, 29:1147-1159.CrossRefPubMed

• Verberne HJ, Habraken JB, van Eck-Smit BL, et al.: Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging 2008, 35:547-553. This retrospective multicenter study in 290 heart failure patients from six sites of five European countries showed a large variation in acquisition parameters, which contributes to the variation of H/M in patients. CrossRefPubMed

10.

• Agostini D, Verberne HJ, Burchert W, et al.: I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008, 35:535-546. The paper re-analyzed pooled data on 290 heart failure patients from six sites in five European countries, which confirmed the prognostic value of H/M in heart failure patients. CrossRefPubMed

11.

• Jacobson AF, Senior R, Cerqueira MD, et al.: Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55:2212-2221. This multicenter, prospective study on 961 heart failure patients from 96 sites provided validation of the independent prognostic value of H/M in assessing heart failure patients.CrossRefPubMed

12.

Inoue Y, Suzuki A, Shirouzu I, et al.: Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003, 10:623-632.CrossRefPubMed

13.

Fletcher AM, Motherwell DW, Small AD, et al.: I-123 MIBG cardiac uptake measurements: limitations of collimator choice and scatter correction in the clinical context. Nucl Med Commun 2010, 31:629-636.PubMed

14.

Farahati J, Bier D, Scheubeck M, et al.: Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med 1997, 38:447-451.PubMed

15.

Ogita H, Shimonagata T, Fukunami M, et al.: Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001, 86:656-660.CrossRefPubMed

16.

Kioka H, Yamada T, Mine T, et al.: Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 2007, 93:1213-1218.CrossRefPubMed

17.

Henderson EB, Kahn JK, Corbett JR, et al.: Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988, 78:1192-1199.PubMed

18.

Nagamachi S, Fujita S, Nishii R, et al.: Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006, 13:34-42.CrossRefPubMed

19.

Dae MW, De Marco T, Botvinick EH, et al.: Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts--implications for clinical studies. J Nucl Med 1992, 33:1444-1450.PubMed

20.

Sisson JC, Wieland DM, Sherman P, et al.: Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987, 28:1620-1624.PubMed

21.

Taki J, Nakajima K, Hwang EH, et al.: Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med Mol Imaging 2000, 27:566-573.CrossRef

22.

• Haider N, Baliga RR, Chandrashekhar Y, et al.: Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovas Imaging 2010, 3:71-75. This is an excellent editorial viewpoint regarding cardiac mIBG imaging, which also presented data of hNET1 expression in heart failure patients.CrossRef

23.

Backs J, Haunstetter A, Gerber SH, et al.: The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 2001, 33:461-472.CrossRefPubMed

24.

Himura Y, Felten SY, Kashiki M, et al.: Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 1993, 88:1299-1309.PubMed

25.

Bohm M, La Rosee K, Schwinger RH, et al.: Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995, 25:146-153.CrossRefPubMed

Title: Variation of Heart-to-Mediastinal Ratio in 123I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections
Authors: Wengen Chen
Qi Cao
Vasken Dilsizian
Publication date: 01-04-2011
Publisher: Current Science Inc.
Published in: Current Cardiology Reports / Issue 2/2011
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-010-0157-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Variation of Heart-to-Mediastinal Ratio in ¹²³I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Metabolic Imaging for Identifying Antecedent Myocardial Ischemia and Acute Coronary Syndrome in the Emergency Department

Risk Scores for Predicting Outcomes in Valvular Heart Disease: How Useful?

Novel F-18–Labeled PET Myocardial Perfusion Tracers: Bench to Bedside

Fatty Acid Imaging of the Heart

The Heterogeneous Biomechanics and Mechanobiology of the Mitral Valve: Implications for Tissue Engineering

Drug-resistant Hypertension: Is Renal Sympathetic Denervation the Answer?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page